<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36038262</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2332-7812</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurology(R) neuroimmunology &amp; neuroinflammation</Title><ISOAbbreviation>Neurol Neuroimmunol Neuroinflamm</ISOAbbreviation></Journal><ArticleTitle>Combined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons With Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e200019</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1212/NXI.0000000000200019</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES">In a phase 1 amyotrophic lateral sclerosis (ALS) study, autologous infusions of expanded regulatory T-lymphocytes (Tregs) combined with subcutaneous interleukin (IL)-2 were safe and well tolerated. Treg suppressive function increased and disease progression stabilized during the study. The present study was conducted to confirm the reliability of these results.</AbstractText><AbstractText Label="METHODS">Participants with ALS underwent leukapheresis, and their Tregs were isolated and expanded in a current Good Manufacturing Practice facility. Seven participants were randomly assigned in a 1:1 ratio to receive Treg infusions (1 &#xd7; 10<sup>6</sup> cells/kg) IV every 4 weeks and IL-2 (2 &#xd7; 10<sup>5</sup> IU/m<sup>2</sup>) injections 3 times/wk or matching placebo in a 24-week randomized controlled trial (RCT). Six participants proceeded into a 24-week dose-escalation open-label extension (OLE). Two additional participants entered directly into the OLE. The OLE included dose escalation of Treg infusions to 2 &#xd7; 10<sup>6</sup> cells/kg and 3 &#xd7; 10<sup>6</sup> cells/kg at 4-week intervals.</AbstractText><AbstractText Label="RESULTS">The Treg/IL-2 treatments were safe and well tolerated, and Treg suppressive function was higher in the active group of the RCT. A meaningful evaluation of progression rates in the RCT between the placebo and active groups was not possible due to the limited number of enrolled participants aggravated by the COVID-19 pandemic. In the 24-week OLE, the Treg/IL-2 treatments were also safe and well tolerated in 8 participants who completed the escalating doses. Treg suppressive function and numbers were increased compared with baseline. Six of 8 participants changed by an average of -2.7 points per the ALS Functional Rating Scale-Revised, whereas the other 2 changed by an average of -10.5 points. Elevated levels of 2 markers of peripheral inflammation (IL-17C and IL-17F) and 2 markers of oxidative stress (oxidized low-density lipoprotein receptor 1 and oxidized LDL) were present in the 2 rapidly progressing participants but not in the slower progressing group.</AbstractText><AbstractText Label="DISCUSSION">Treg/IL-2 treatments were safe and well tolerated in the RCT and OLE with higher Treg suppressive function. During the OLE, 6 of 8 participants showed slow to no progression. The 2 of 8 rapid progressors had elevated markers of oxidative stress and inflammation, which may help delineate responsiveness to therapy. Whether Treg/IL-2 treatments can slow disease progression requires a larger clinical study (ClinicalTrials.gov number, NCT04055623).</AbstractText><AbstractText Label="CLASSIFICATION OF EVIDENCE">This study provides Class IV evidence that Treg infusions and IL-2 injections are safe and effective for patients with ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thonhoff</LastName><ForeName>Jason R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>From the Houston Methodist Neurological Institute (J.R.T., D.R.B., P.A.M., W.Z., A.D.T., S.H.A.), Houston Methodist Hospital Research Institute, Stanley H. Appel Department of Neurology, Houston, TX; Neurological Clinical Research Institute (J.D.B., S.P., M.C.), Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, MA; Biostatistics Center (E.A.M.), Massachusetts General Hospital, Boston, MA; Harvard Medical School (E.A.M.), Boston, MA; Department of Pediatric Surgery (F.T.), McGovern Medical School, UTHealth-The University of Texas Health Science Center at Houston, Houston, TX; and Center for Immunology and Inflammatory Diseases (J.J.M.), Massachusetts General Hospital, Boston, MA; and Harvard Medical School (J.J.M.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>From the Houston Methodist Neurological Institute (J.R.T., D.R.B., P.A.M., W.Z., A.D.T., S.H.A.), Houston Methodist Hospital Research Institute, Stanley H. Appel Department of Neurology, Houston, TX; Neurological Clinical Research Institute (J.D.B., S.P., M.C.), Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, MA; Biostatistics Center (E.A.M.), Massachusetts General Hospital, Boston, MA; Harvard Medical School (E.A.M.), Boston, MA; Department of Pediatric Surgery (F.T.), McGovern Medical School, UTHealth-The University of Texas Health Science Center at Houston, Houston, TX; and Center for Immunology and Inflammatory Diseases (J.J.M.), Massachusetts General Hospital, Boston, MA; and Harvard Medical School (J.J.M.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macklin</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>From the Houston Methodist Neurological Institute (J.R.T., D.R.B., P.A.M., W.Z., A.D.T., S.H.A.), Houston Methodist Hospital Research Institute, Stanley H. Appel Department of Neurology, Houston, TX; Neurological Clinical Research Institute (J.D.B., S.P., M.C.), Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, MA; Biostatistics Center (E.A.M.), Massachusetts General Hospital, Boston, MA; Harvard Medical School (E.A.M.), Boston, MA; Department of Pediatric Surgery (F.T.), McGovern Medical School, UTHealth-The University of Texas Health Science Center at Houston, Houston, TX; and Center for Immunology and Inflammatory Diseases (J.J.M.), Massachusetts General Hospital, Boston, MA; and Harvard Medical School (J.J.M.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beers</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>From the Houston Methodist Neurological Institute (J.R.T., D.R.B., P.A.M., W.Z., A.D.T., S.H.A.), Houston Methodist Hospital Research Institute, Stanley H. Appel Department of Neurology, Houston, TX; Neurological Clinical Research Institute (J.D.B., S.P., M.C.), Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, MA; Biostatistics Center (E.A.M.), Massachusetts General Hospital, Boston, MA; Harvard Medical School (E.A.M.), Boston, MA; Department of Pediatric Surgery (F.T.), McGovern Medical School, UTHealth-The University of Texas Health Science Center at Houston, Houston, TX; and Center for Immunology and Inflammatory Diseases (J.J.M.), Massachusetts General Hospital, Boston, MA; and Harvard Medical School (J.J.M.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendoza</LastName><ForeName>Patricia A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>From the Houston Methodist Neurological Institute (J.R.T., D.R.B., P.A.M., W.Z., A.D.T., S.H.A.), Houston Methodist Hospital Research Institute, Stanley H. Appel Department of Neurology, Houston, TX; Neurological Clinical Research Institute (J.D.B., S.P., M.C.), Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, MA; Biostatistics Center (E.A.M.), Massachusetts General Hospital, Boston, MA; Harvard Medical School (E.A.M.), Boston, MA; Department of Pediatric Surgery (F.T.), McGovern Medical School, UTHealth-The University of Texas Health Science Center at Houston, Houston, TX; and Center for Immunology and Inflammatory Diseases (J.J.M.), Massachusetts General Hospital, Boston, MA; and Harvard Medical School (J.J.M.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Weihua</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>From the Houston Methodist Neurological Institute (J.R.T., D.R.B., P.A.M., W.Z., A.D.T., S.H.A.), Houston Methodist Hospital Research Institute, Stanley H. Appel Department of Neurology, Houston, TX; Neurological Clinical Research Institute (J.D.B., S.P., M.C.), Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, MA; Biostatistics Center (E.A.M.), Massachusetts General Hospital, Boston, MA; Harvard Medical School (E.A.M.), Boston, MA; Department of Pediatric Surgery (F.T.), McGovern Medical School, UTHealth-The University of Texas Health Science Center at Houston, Houston, TX; and Center for Immunology and Inflammatory Diseases (J.J.M.), Massachusetts General Hospital, Boston, MA; and Harvard Medical School (J.J.M.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thome</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>From the Houston Methodist Neurological Institute (J.R.T., D.R.B., P.A.M., W.Z., A.D.T., S.H.A.), Houston Methodist Hospital Research Institute, Stanley H. Appel Department of Neurology, Houston, TX; Neurological Clinical Research Institute (J.D.B., S.P., M.C.), Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, MA; Biostatistics Center (E.A.M.), Massachusetts General Hospital, Boston, MA; Harvard Medical School (E.A.M.), Boston, MA; Department of Pediatric Surgery (F.T.), McGovern Medical School, UTHealth-The University of Texas Health Science Center at Houston, Houston, TX; and Center for Immunology and Inflammatory Diseases (J.J.M.), Massachusetts General Hospital, Boston, MA; and Harvard Medical School (J.J.M.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Triolo</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>From the Houston Methodist Neurological Institute (J.R.T., D.R.B., P.A.M., W.Z., A.D.T., S.H.A.), Houston Methodist Hospital Research Institute, Stanley H. Appel Department of Neurology, Houston, TX; Neurological Clinical Research Institute (J.D.B., S.P., M.C.), Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, MA; Biostatistics Center (E.A.M.), Massachusetts General Hospital, Boston, MA; Harvard Medical School (E.A.M.), Boston, MA; Department of Pediatric Surgery (F.T.), McGovern Medical School, UTHealth-The University of Texas Health Science Center at Houston, Houston, TX; and Center for Immunology and Inflammatory Diseases (J.J.M.), Massachusetts General Hospital, Boston, MA; and Harvard Medical School (J.J.M.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>James J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>From the Houston Methodist Neurological Institute (J.R.T., D.R.B., P.A.M., W.Z., A.D.T., S.H.A.), Houston Methodist Hospital Research Institute, Stanley H. Appel Department of Neurology, Houston, TX; Neurological Clinical Research Institute (J.D.B., S.P., M.C.), Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, MA; Biostatistics Center (E.A.M.), Massachusetts General Hospital, Boston, MA; Harvard Medical School (E.A.M.), Boston, MA; Department of Pediatric Surgery (F.T.), McGovern Medical School, UTHealth-The University of Texas Health Science Center at Houston, Houston, TX; and Center for Immunology and Inflammatory Diseases (J.J.M.), Massachusetts General Hospital, Boston, MA; and Harvard Medical School (J.J.M.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Houston Methodist Neurological Institute (J.R.T., D.R.B., P.A.M., W.Z., A.D.T., S.H.A.), Houston Methodist Hospital Research Institute, Stanley H. Appel Department of Neurology, Houston, TX; Neurological Clinical Research Institute (J.D.B., S.P., M.C.), Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, MA; Biostatistics Center (E.A.M.), Massachusetts General Hospital, Boston, MA; Harvard Medical School (E.A.M.), Boston, MA; Department of Pediatric Surgery (F.T.), McGovern Medical School, UTHealth-The University of Texas Health Science Center at Houston, Houston, TX; and Center for Immunology and Inflammatory Diseases (J.J.M.), Massachusetts General Hospital, Boston, MA; and Harvard Medical School (J.J.M.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Houston Methodist Neurological Institute (J.R.T., D.R.B., P.A.M., W.Z., A.D.T., S.H.A.), Houston Methodist Hospital Research Institute, Stanley H. Appel Department of Neurology, Houston, TX; Neurological Clinical Research Institute (J.D.B., S.P., M.C.), Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, MA; Biostatistics Center (E.A.M.), Massachusetts General Hospital, Boston, MA; Harvard Medical School (E.A.M.), Boston, MA; Department of Pediatric Surgery (F.T.), McGovern Medical School, UTHealth-The University of Texas Health Science Center at Houston, Houston, TX; and Center for Immunology and Inflammatory Diseases (J.J.M.), Massachusetts General Hospital, Boston, MA; and Harvard Medical School (J.J.M.), Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appel</LastName><ForeName>Stanley H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>From the Houston Methodist Neurological Institute (J.R.T., D.R.B., P.A.M., W.Z., A.D.T., S.H.A.), Houston Methodist Hospital Research Institute, Stanley H. Appel Department of Neurology, Houston, TX; Neurological Clinical Research Institute (J.D.B., S.P., M.C.), Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, MA; Biostatistics Center (E.A.M.), Massachusetts General Hospital, Boston, MA; Harvard Medical School (E.A.M.), Boston, MA; Department of Pediatric Surgery (F.T.), McGovern Medical School, UTHealth-The University of Texas Health Science Center at Houston, Houston, TX; and Center for Immunology and Inflammatory Diseases (J.J.M.), Massachusetts General Hospital, Boston, MA; and Harvard Medical School (J.J.M.), Boston, MA. sappel@houstonmethodist.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04055623</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurol Neuroimmunol Neuroinflamm</MedlineTA><NlmUniqueID>101636388</NlmUniqueID><ISSNLinking>2332-7812</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>29</Day><Hour>21</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36038262</ArticleId><ArticleId IdType="pmc">PMC9423710</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000200019</ArticleId><ArticleId IdType="pii">9/6/e200019</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6(4):345-352.</Citation><ArticleIdList><ArticleId IdType="pubmed">15785760</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaguchi S, Ono M, Setoguchi R, et al. . Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006;212:8-27.</Citation><ArticleIdList><ArticleId IdType="pubmed">16903903</ArticleId></ArticleIdList></Reference><Reference><Citation>Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057-1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">12522256</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775-787.</Citation><ArticleIdList><ArticleId IdType="pubmed">18510923</ArticleId></ArticleIdList></Reference><Reference><Citation>Faridar A, Thome AD, Zhao W, et al. . Restoring regulatory T-cell dysfunction in Alzheimer's disease through ex vivo expansion. Brain Commun. 2020;2:fcaa112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7472911</ArticleId><ArticleId IdType="pubmed">32954348</ArticleId></ArticleIdList></Reference><Reference><Citation>Thome AD, Atassi F, Wang J, et al. . Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson's disease. NPJ Parkinsons Dis. 2021;7(1):41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8119976</ArticleId><ArticleId IdType="pubmed">33986285</ArticleId></ArticleIdList></Reference><Reference><Citation>Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004;199(7):971-979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2211881</ArticleId><ArticleId IdType="pubmed">15067033</ArticleId></ArticleIdList></Reference><Reference><Citation>Goverman JM. Regulatory T cells in multiple sclerosis. N Engl J Med. 2021;384(6):578-580.</Citation><ArticleIdList><ArticleId IdType="pubmed">33567197</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, et al. . Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134(pt 5):1293-1314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097891</ArticleId><ArticleId IdType="pubmed">21596768</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Wang J, et al. . ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight. 2017;2(5):e89530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333967</ArticleId><ArticleId IdType="pubmed">28289705</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, et al. . Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5(1):64-79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsuliman A, Appel SH, Beers DR, et al. . A robust, good manufacturing practice-compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy. Cytotherapy. 2016;18(10):1312-1324.</Citation><ArticleIdList><ArticleId IdType="pubmed">27497700</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Beers DR, Zhao W, et al. . Expanded autologous regulatory T-lymphocyte infusions in ALS: a phase I, first-in-human study. Neurol Neuroimmunol Neuroinflamm. 2018;5(4):e465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961523</ArticleId><ArticleId IdType="pubmed">29845093</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Thonhoff JR, Faridar A, et al. . Tregs attenuate peripheral oxidative stress and acute phase proteins in ALS. Ann Neurol. 2022;92(2):195-200.</Citation><ArticleIdList><ArticleId IdType="pubmed">35445431</ArticleId></ArticleIdList></Reference><Reference><Citation>Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118(pt 3):707-719.</Citation><ArticleIdList><ArticleId IdType="pubmed">7600088</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SH, Dong C. IL-17F: regulation, signaling and function in inflammation. Cytokine. 2009;46(1):7-11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663007</ArticleId><ArticleId IdType="pubmed">19233684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez-Carrozzi V, Sambandam A, Luis E, et al. . IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol. 2011;12:1159-1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">21993848</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenen HJPM, Smeets RL, Vink PM, van Rijssen E, Boots AMH, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood. 2008;112(6):2340-2352.</Citation><ArticleIdList><ArticleId IdType="pubmed">18617638</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, Gunther R, Akgun K, Hermann A, Ziemssen T. Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. Sci Rep. 2020;10(1):5941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125229</ArticleId><ArticleId IdType="pubmed">32246039</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas MC, Stein DP, Otero C, Sekul E, Cupler EJ, McCrosky S. Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy. Arch Neurol. 1994;51(9):861-864.</Citation><ArticleIdList><ArticleId IdType="pubmed">8080385</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>